Publications by authors named "C Losada"
Article Synopsis
- - The study assessed the effectiveness of a COVID-19 Sanofi booster vaccine by measuring neutralizing antibody levels in COVAIL recipients as a predictor of COVID-19 risk.
- - Higher levels of antibody titers were found to be associated with a lower risk of COVID-19, indicated by adjusted hazard ratios of 0.30 and 0.25 for different titer measurements.
- - An increase of 10-fold in the weighted average titer substantially reduced the risk, suggesting that higher antibody levels can offer better protection against the virus.
Background And Purpose: Endovascular robotic devices may enable experienced neurointerventionalists to remotely perform endovascular thrombectomy. This study aimed to assess the feasibility, safety, and efficacy of robot-assisted endovascular thrombectomy compared with manual procedures by operators with varying levels of experience, using a 3D printed neurovascular model.
Materials And Methods: M1 MCA occlusions were simulated in a 3D printed neurovascular model, linked to a CorPath GRX robot in a biplane angiography suite.
Article Synopsis
- Vaccine protection against SARS-CoV-2 diminishes over time, making updated boosters necessary, as assessed in a phase 2 clinical trial with various mRNA and protein-based vaccines targeting multiple variants.* -
- The trial measured safe levels of immunity by evaluating pseudovirus neutralization and found that variant-containing vaccines performed better than wild-type ones against different strains.* -
- Updated vaccines targeting variants like Beta or Omicron BA.1 show strong neutralizing antibody responses across various SARS-CoV-2 strains while still maintaining immunity to the original virus.*
We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with a variant vaccine did not increase the magnitude or the durability of the serological responses compared to a single variant vaccine boost.
View Article and Find Full Text PDFPeople living with HIV (PLH) experience higher rates of HPV infection as well as an increased risk of HPV-related disease, including malignancies. Although they are considered a high-priority group for HPV vaccination, there are limited data regarding the long-term immunogenicity and efficacy of HPV vaccines in this population. Seroconversion rates and geometric mean titers elicited by vaccination are lower in PLH compared to immunocompetent participants, especially in individuals with CD4 counts below 200 cells/mm and a detectable viral load.
View Article and Find Full Text PDF